Cinclus Pharma (CINPHA) Stifel 2025 Healthcare Conference summary

Company background and asset overview

• Team and asset originate from AstraZeneca, leveraging deep industry experience.

• Lead asset, linaprazan glurate, is a next-generation PCAB targeting GERD.

• Focus is on achieving near-complete 24-hour acid control for patients.

Clinical development and trial design

• Currently in Phase III, with the first trial recruiting over 500 patients in Europe.

• Primary endpoint is healing within four weeks for severe GERD patients; secondary endpoints include symptom relief and maintenance.

• Phase III design aims to demonstrate superiority over PPIs in both healing and symptom relief, with faster results.

• Improved formulation for Phase III enhances acid control and manufacturing efficiency.

• Recruitment is progressing as planned, with patient randomization ongoing.

Market positioning and commercial strategy

• Targeting a niche of severe GERD patients not helped by current therapies, aiming for premium pricing.

• Strategy focuses on specialist gastroenterologists, mirroring recent competitor pivots.

• Market entry expected in 2029-2030, with dynamic opportunities as PCAB awareness grows.

• Zentiva partnership for Europe validates asset value and supports pricing strategy.

• U.S. rights retained, with future commercial options considered post-Phase III readout.